Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Avaliação da adição do medicamento imunoterápico atezolizumabe ao tratamento quimioterápico padrão para carcinomas neuroendócrinos avançados ou metastáticos com origem fora do pulmão

10 de novembro de 2026 atualizado por: National Cancer Institute (NCI)

Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.

Visão geral do estudo

Descrição detalhada

PRIMARY OBJECTIVES:

I. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus induction platinum/etoposide alone (Arm 3).

II. Compare the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2) versus induction platinum/etoposide alone (Arm 3).

III. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2).

SECONDARY OBJECTIVES:

I. To compare overall survival (OS), measured from start of observation/maintenance, across arms.

II. To compare progression free survival (PFS) (measured from randomization and measured from start of observation/maintenance) across arms.

III. To compare objective response rate (ORR = confirmed and unconfirmed partial response [PR] + confirmed and unconfirmed complete response [CR]) across arms among patients with measurable disease at randomization.

IV. To compare clinical benefit rate (CBR = confirmed and unconfirmed PR + confirmed and unconfirmed CR + stable disease [SD]) across arms among patients with measurable disease at randomization.

V. To compare duration of response (DOR) across arms. VI. To evaluate the safety and tolerability of each arm.

ADDITIONAL OBJECTIVE:

I. To bank tumor and blood samples for future biomarker correlative studies.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: During induction phase, patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.

ARM II (CLOSED TO ACCRUAL 7/9/26): During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.

ARM III: During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.

Patients in all arms also undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) throughout the trial and blood sample collection on study.

After completion of study treatment, patients are followed up for 5 years.

Tipo de estudo

Intervencional

Inscrição (Estimado)

189

Estágio

  • Fase 2
  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Alaska
      • Anchorage, Alaska, Estados Unidos, 99508
        • Suspenso
        • Alaska Women's Cancer Care
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85004
      • Phoenix, Arizona, Estados Unidos, 85054
        • Recrutamento
        • Mayo Clinic Hospital in Arizona
        • Investigador principal:
          • Jacob Orme
        • Contato:
          • Site Public Contact
          • Número de telefone: 855-776-0015
    • California
      • Anaheim, California, Estados Unidos, 92806
        • Recrutamento
        • Kaiser Permanente-Anaheim
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Auburn, California, Estados Unidos, 95602
      • Auburn, California, Estados Unidos, 95603
        • Recrutamento
        • Sutter Cancer Centers Radiation Oncology Services-Auburn
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Baldwin Park, California, Estados Unidos, 91706
        • Recrutamento
        • Kaiser Permanente-Baldwin Park
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Bellflower, California, Estados Unidos, 90706
        • Recrutamento
        • Kaiser Permanente-Bellflower
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Berkeley, California, Estados Unidos, 94704
        • Recrutamento
        • Alta Bates Summit Medical Center-Herrick Campus
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Cameron Park, California, Estados Unidos, 95682
        • Recrutamento
        • Sutter Cancer Centers Radiation Oncology Services-Cameron Park
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Carmichael, California, Estados Unidos, 95608
      • Carmichael, California, Estados Unidos, 95608
      • Elk Grove, California, Estados Unidos, 95758
      • Fontana, California, Estados Unidos, 92335
        • Recrutamento
        • Kaiser Permanente-Fontana
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Fremont, California, Estados Unidos, 94538
        • Recrutamento
        • Palo Alto Medical Foundation-Fremont
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Harbor City, California, Estados Unidos, 90710
        • Recrutamento
        • Kaiser Permanente South Bay
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Irvine, California, Estados Unidos, 92618
        • Recrutamento
        • Kaiser Permanente-Irvine
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Los Angeles, California, Estados Unidos, 90027
        • Recrutamento
        • Kaiser Permanente Los Angeles Medical Center
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Los Angeles, California, Estados Unidos, 90034
        • Recrutamento
        • Kaiser Permanente West Los Angeles
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Modesto, California, Estados Unidos, 95355
      • Mountain View, California, Estados Unidos, 94040
        • Recrutamento
        • Palo Alto Medical Foundation-Camino Division
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Ontario, California, Estados Unidos, 91761
        • Recrutamento
        • Kaiser Permanente-Ontario
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Palo Alto, California, Estados Unidos, 94301
        • Recrutamento
        • Palo Alto Medical Foundation Health Care
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Panorama City, California, Estados Unidos, 91402
        • Recrutamento
        • Kaiser Permanente - Panorama City
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Riverside, California, Estados Unidos, 92505
        • Recrutamento
        • Kaiser Permanente-Riverside
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Rocklin, California, Estados Unidos, 95765
      • Roseville, California, Estados Unidos, 95661
        • Recrutamento
        • Sutter Cancer Centers Radiation Oncology Services-Roseville
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Roseville, California, Estados Unidos, 95661
      • Sacramento, California, Estados Unidos, 95816
      • Sacramento, California, Estados Unidos, 95816
      • San Diego, California, Estados Unidos, 92120
        • Recrutamento
        • Kaiser Permanente-San Diego Zion
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • San Francisco, California, Estados Unidos, 94115
        • Recrutamento
        • California Pacific Medical Center-Pacific Campus
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • San Marcos, California, Estados Unidos, 92078
        • Recrutamento
        • Kaiser Permanente-San Marcos
        • Contato:
        • Investigador principal:
          • Helen H. Moon
      • Santa Cruz, California, Estados Unidos, 95065
        • Recrutamento
        • Palo Alto Medical Foundation-Santa Cruz
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Santa Rosa, California, Estados Unidos, 95403
        • Recrutamento
        • Sutter Pacific Medical Foundation
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Sunnyvale, California, Estados Unidos, 94086
        • Recrutamento
        • Palo Alto Medical Foundation-Sunnyvale
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Vallejo, California, Estados Unidos, 94589
        • Recrutamento
        • Sutter Solano Medical Center/Cancer Center
        • Investigador principal:
          • Kristie A. Bobolis
        • Contato:
      • Woodland, California, Estados Unidos, 95695
      • Woodland Hills, California, Estados Unidos, 91367
        • Recrutamento
        • Kaiser Permanente-Woodland Hills
        • Contato:
        • Investigador principal:
          • Helen H. Moon
    • Colorado
      • Denver, Colorado, Estados Unidos, 80210
      • Littleton, Colorado, Estados Unidos, 80122
      • Parker, Colorado, Estados Unidos, 80138
    • Connecticut
      • Derby, Connecticut, Estados Unidos, 06418
        • Recrutamento
        • Smilow Cancer Hospital-Derby Care Center
        • Contato:
        • Investigador principal:
          • Matthew Austin
      • Fairfield, Connecticut, Estados Unidos, 06824
        • Recrutamento
        • Smilow Cancer Hospital Care Center-Fairfield
        • Contato:
        • Investigador principal:
          • Matthew Austin
      • Glastonbury, Connecticut, Estados Unidos, 06033
        • Suspenso
        • Smilow Cancer Hospital Care Center at Glastonbury
      • Greenwich, Connecticut, Estados Unidos, 06830
        • Recrutamento
        • Smilow Cancer Hospital Care Center at Greenwich
        • Contato:
        • Investigador principal:
          • Matthew Austin
      • Guilford, Connecticut, Estados Unidos, 06437
        • Recrutamento
        • Smilow Cancer Hospital Care Center - Guilford
        • Contato:
        • Investigador principal:
          • Matthew Austin
      • Hartford, Connecticut, Estados Unidos, 06105
        • Suspenso
        • Smilow Cancer Hospital Care Center at Saint Francis
      • New Haven, Connecticut, Estados Unidos, 06520
        • Recrutamento
        • Yale University
        • Contato:
        • Investigador principal:
          • Matthew Austin
      • North Haven, Connecticut, Estados Unidos, 06473
        • Recrutamento
        • Yale-New Haven Hospital North Haven Medical Center
        • Contato:
        • Investigador principal:
          • Matthew Austin
      • Stamford, Connecticut, Estados Unidos, 06902
        • Recrutamento
        • Smilow Cancer Hospital Care Center at Long Ridge
        • Contato:
        • Investigador principal:
          • Matthew Austin
      • Torrington, Connecticut, Estados Unidos, 06790
        • Recrutamento
        • Smilow Cancer Hospital-Torrington Care Center
        • Contato:
        • Investigador principal:
          • Matthew Austin
      • Trumbull, Connecticut, Estados Unidos, 06611
        • Recrutamento
        • Smilow Cancer Hospital Care Center-Trumbull
        • Contato:
        • Investigador principal:
          • Matthew Austin
      • Waterbury, Connecticut, Estados Unidos, 06708
        • Recrutamento
        • Smilow Cancer Hospital-Waterbury Care Center
        • Contato:
        • Investigador principal:
          • Matthew Austin
      • Waterford, Connecticut, Estados Unidos, 06385
        • Recrutamento
        • Smilow Cancer Hospital Care Center - Waterford
        • Contato:
        • Investigador principal:
          • Matthew Austin
    • Florida
      • Fort Lauderdale, Florida, Estados Unidos, 33308
        • Recrutamento
        • Holy Cross Hospital
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • Jacksonville, Florida, Estados Unidos, 32224-9980
        • Recrutamento
        • Mayo Clinic in Florida
        • Investigador principal:
          • Jacob Orme
        • Contato:
          • Site Public Contact
          • Número de telefone: 855-776-0015
      • Tampa, Florida, Estados Unidos, 33612
        • Recrutamento
        • Moffitt Cancer Center
        • Contato:
        • Investigador principal:
          • Mintallah Haider
    • Hawaii
      • Honolulu, Hawaii, Estados Unidos, 96813
        • Recrutamento
        • Hawaii Cancer Care Inc - Waterfront Plaza
        • Contato:
        • Investigador principal:
          • Elizabeth S. Nakasone
      • Honolulu, Hawaii, Estados Unidos, 96813
        • Recrutamento
        • Queen's Cancer Cenrer - POB I
        • Contato:
          • Site Public Contact
          • Número de telefone: 808-532-0315
        • Investigador principal:
          • Elizabeth S. Nakasone
      • Honolulu, Hawaii, Estados Unidos, 96813
        • Recrutamento
        • Queen's Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 808-545-8548
        • Investigador principal:
          • Elizabeth S. Nakasone
      • Honolulu, Hawaii, Estados Unidos, 96813
        • Recrutamento
        • Straub Clinic and Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 808-522-4333
        • Investigador principal:
          • Elizabeth S. Nakasone
      • Honolulu, Hawaii, Estados Unidos, 96813
        • Recrutamento
        • University of Hawaii Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 808-586-2979
        • Investigador principal:
          • Elizabeth S. Nakasone
      • Honolulu, Hawaii, Estados Unidos, 96817
        • Recrutamento
        • Queen's Cancer Center - Kuakini
        • Contato:
          • Site Public Contact
          • Número de telefone: 808-531-8521
        • Investigador principal:
          • Elizabeth S. Nakasone
      • ‘Aiea, Hawaii, Estados Unidos, 96701
        • Recrutamento
        • Hawaii Cancer Care - Westridge
        • Contato:
        • Investigador principal:
          • Elizabeth S. Nakasone
      • ‘Aiea, Hawaii, Estados Unidos, 96701
        • Suspenso
        • Pali Momi Medical Center
      • ‘Ewa Beach, Hawaii, Estados Unidos, 96706
        • Recrutamento
        • The Queen's Medical Center - West Oahu
        • Contato:
        • Investigador principal:
          • Elizabeth S. Nakasone
    • Idaho
      • Coeur d'Alene, Idaho, Estados Unidos, 83814
        • Recrutamento
        • Kootenai Health - Coeur d'Alene
        • Investigador principal:
          • John M. Schallenkamp
        • Contato:
      • Nampa, Idaho, Estados Unidos, 83687
        • Recrutamento
        • Saint Alphonsus Cancer Care Center-Nampa
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Post Falls, Idaho, Estados Unidos, 83854
        • Recrutamento
        • Kootenai Clinic Cancer Services - Post Falls
        • Investigador principal:
          • John M. Schallenkamp
        • Contato:
      • Sandpoint, Idaho, Estados Unidos, 83864
        • Recrutamento
        • Kootenai Clinic Cancer Services - Sandpoint
        • Investigador principal:
          • John M. Schallenkamp
        • Contato:
    • Illinois
      • Aurora, Illinois, Estados Unidos, 60504
        • Suspenso
        • Rush-Copley Medical Center
      • Centralia, Illinois, Estados Unidos, 62801
        • Recrutamento
        • Centralia Oncology Clinic
        • Investigador principal:
          • Bryan A. Faller
        • Contato:
      • Chicago, Illinois, Estados Unidos, 60637
        • Recrutamento
        • University of Chicago Comprehensive Cancer Center
        • Contato:
        • Investigador principal:
          • Ardaman Shergill
      • Chicago, Illinois, Estados Unidos, 60611
        • Recrutamento
        • Northwestern University
        • Investigador principal:
          • Mary F. Mulcahy
        • Contato:
      • Danville, Illinois, Estados Unidos, 61832
        • Recrutamento
        • Carle at The Riverfront
        • Investigador principal:
          • Vamsi K. Vasireddy
        • Contato:
      • DeKalb, Illinois, Estados Unidos, 60115
        • Recrutamento
        • Northwestern Medicine Cancer Center Kishwaukee
        • Investigador principal:
          • Mary F. Mulcahy
        • Contato:
      • Decatur, Illinois, Estados Unidos, 62526
        • Recrutamento
        • Cancer Care Specialists of Illinois - Decatur
        • Investigador principal:
          • Bryan A. Faller
        • Contato:
      • Decatur, Illinois, Estados Unidos, 62526
        • Recrutamento
        • Decatur Memorial Hospital
        • Investigador principal:
          • Bryan A. Faller
        • Contato:
      • Effingham, Illinois, Estados Unidos, 62401
        • Recrutamento
        • Carle Physician Group-Effingham
        • Contato:
        • Investigador principal:
          • Vamsi K. Vasireddy
      • Effingham, Illinois, Estados Unidos, 62401
        • Recrutamento
        • Crossroads Cancer Center
        • Investigador principal:
          • Bryan A. Faller
        • Contato:
      • Geneva, Illinois, Estados Unidos, 60134
        • Recrutamento
        • Northwestern Medicine Cancer Center Delnor
        • Investigador principal:
          • Mary F. Mulcahy
        • Contato:
      • Glenview, Illinois, Estados Unidos, 60026
        • Recrutamento
        • Northwestern Medicine Glenview Outpatient Center
        • Investigador principal:
          • Mary F. Mulcahy
        • Contato:
          • Site Public Contact
          • Número de telefone: 312-695-1102
      • Grayslake, Illinois, Estados Unidos, 60030
        • Recrutamento
        • Northwestern Medicine Grayslake Outpatient Center
        • Investigador principal:
          • Mary F. Mulcahy
        • Contato:
          • Site Public Contact
          • Número de telefone: 312-695-1102
      • Harvey, Illinois, Estados Unidos, 60426
        • Recrutamento
        • Ingalls Memorial Hospital
        • Investigador principal:
          • James A. Wallace
        • Contato:
      • Lake Forest, Illinois, Estados Unidos, 60045
        • Recrutamento
        • Northwestern Medicine Lake Forest Hospital
        • Investigador principal:
          • Mary F. Mulcahy
        • Contato:
      • Mattoon, Illinois, Estados Unidos, 61938
        • Recrutamento
        • Carle Physician Group-Mattoon/Charleston
        • Contato:
        • Investigador principal:
          • Vamsi K. Vasireddy
      • Mount Vernon, Illinois, Estados Unidos, 62864
        • Recrutamento
        • SSM Health Good Samaritan
        • Investigador principal:
          • Jay W. Carlson
        • Contato:
      • New Lenox, Illinois, Estados Unidos, 60451
        • Recrutamento
        • UC Comprehensive Cancer Center at Silver Cross
        • Contato:
        • Investigador principal:
          • Ardaman Shergill
      • Normal, Illinois, Estados Unidos, 61761
        • Recrutamento
        • Carle BroMenn Medical Center
        • Investigador principal:
          • Vamsi K. Vasireddy
        • Contato:
      • Normal, Illinois, Estados Unidos, 61761
        • Recrutamento
        • Carle Cancer Institute Normal
        • Investigador principal:
          • Vamsi K. Vasireddy
        • Contato:
      • O'Fallon, Illinois, Estados Unidos, 62269
        • Recrutamento
        • Cancer Care Center of O'Fallon
        • Investigador principal:
          • Bryan A. Faller
        • Contato:
      • Orland Park, Illinois, Estados Unidos, 60462
        • Recrutamento
        • University of Chicago Medicine-Orland Park
        • Contato:
        • Investigador principal:
          • Ardaman Shergill
      • Orland Park, Illinois, Estados Unidos, 60462
      • Rockford, Illinois, Estados Unidos, 61114
        • Recrutamento
        • UW Health Carbone Cancer Center Rockford
        • Contato:
        • Investigador principal:
          • Fahrettin Covut
      • Springfield, Illinois, Estados Unidos, 62702
        • Recrutamento
        • Southern Illinois University School of Medicine
        • Investigador principal:
          • Bryan A. Faller
        • Contato:
          • Site Public Contact
          • Número de telefone: 217-545-7929
      • Springfield, Illinois, Estados Unidos, 62702
        • Recrutamento
        • Springfield Clinic
        • Investigador principal:
          • Bryan A. Faller
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-444-7541
      • Springfield, Illinois, Estados Unidos, 62781
        • Recrutamento
        • Springfield Memorial Hospital
        • Investigador principal:
          • Bryan A. Faller
        • Contato:
      • Urbana, Illinois, Estados Unidos, 61801
        • Recrutamento
        • Carle Cancer Center
        • Contato:
        • Investigador principal:
          • Vamsi K. Vasireddy
      • Warrenville, Illinois, Estados Unidos, 60555
        • Recrutamento
        • Northwestern Medicine Cancer Center Warrenville
        • Investigador principal:
          • Mary F. Mulcahy
        • Contato:
      • Yorkville, Illinois, Estados Unidos, 60560
        • Suspenso
        • Rush-Copley Healthcare Center
    • Indiana
      • Crown Point, Indiana, Estados Unidos, 46307
        • Recrutamento
        • UChicago Medicine Northwest Indiana
        • Investigador principal:
          • Ardaman Shergill
        • Contato:
    • Iowa
      • Ames, Iowa, Estados Unidos, 50010
        • Recrutamento
        • Mary Greeley Medical Center
        • Investigador principal:
          • Joseph J. Merchant
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-956-4132
      • Ames, Iowa, Estados Unidos, 50010
        • Recrutamento
        • McFarland Clinic - Ames
        • Investigador principal:
          • Joseph J. Merchant
        • Contato:
      • Ankeny, Iowa, Estados Unidos, 50023
        • Recrutamento
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-241-3305
        • Investigador principal:
          • Seema Harichand-Herdt
      • Boone, Iowa, Estados Unidos, 50036
        • Suspenso
        • McFarland Clinic - Boone
      • Carroll, Iowa, Estados Unidos, 51401
        • Recrutamento
        • Saint Anthony Regional Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-689-7658
          • E-mail: sbenson@iora.org
        • Investigador principal:
          • Seema Harichand-Herdt
      • Clive, Iowa, Estados Unidos, 50325
        • Recrutamento
        • Mercy Cancer Center-West Lakes
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-241-3305
        • Investigador principal:
          • Richard L. Deming
      • Clive, Iowa, Estados Unidos, 50325
        • Recrutamento
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-241-3305
        • Investigador principal:
          • Seema Harichand-Herdt
      • Creston, Iowa, Estados Unidos, 50801
        • Ativo, não recrutando
        • Greater Regional Medical Center
      • Des Moines, Iowa, Estados Unidos, 50314
        • Recrutamento
        • Broadlawns Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-282-2200
        • Investigador principal:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Estados Unidos, 50314
        • Recrutamento
        • Mercy Medical Center - Des Moines
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-241-3305
        • Investigador principal:
          • Richard L. Deming
      • Des Moines, Iowa, Estados Unidos, 50309
        • Recrutamento
        • Iowa Methodist Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-241-6727
        • Investigador principal:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Estados Unidos, 50309
        • Recrutamento
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-241-3305
        • Investigador principal:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Estados Unidos, 50314
        • Recrutamento
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-241-3305
        • Investigador principal:
          • Seema Harichand-Herdt
      • Fort Dodge, Iowa, Estados Unidos, 50501
        • Recrutamento
        • McFarland Clinic - Trinity Cancer Center
        • Investigador principal:
          • Joseph J. Merchant
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-956-4132
      • Jefferson, Iowa, Estados Unidos, 50129
        • Suspenso
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Estados Unidos, 50158
        • Recrutamento
        • McFarland Clinic - Marshalltown
        • Investigador principal:
          • Joseph J. Merchant
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-956-4132
      • Waukee, Iowa, Estados Unidos, 50263
        • Recrutamento
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-241-3305
        • Investigador principal:
          • Seema Harichand-Herdt
      • West Des Moines, Iowa, Estados Unidos, 50266
        • Recrutamento
        • Mercy Medical Center-West Lakes
        • Contato:
          • Site Public Contact
          • Número de telefone: 515-241-3305
        • Investigador principal:
          • Richard L. Deming
    • Louisiana
      • Baton Rouge, Louisiana, Estados Unidos, 70805
        • Recrutamento
        • LSU Health Baton Rouge-North Clinic
        • Contato:
        • Investigador principal:
          • Marshall P. Stagg
      • Baton Rouge, Louisiana, Estados Unidos, 70808
        • Recrutamento
        • Our Lady of the Lake Physician Group
        • Contato:
        • Investigador principal:
          • Marshall P. Stagg
      • Metairie, Louisiana, Estados Unidos, 70006
        • Recrutamento
        • East Jefferson General Hospital
        • Contato:
        • Investigador principal:
          • Tara Castellano
      • Metairie, Louisiana, Estados Unidos, 70006
        • Recrutamento
        • LSU Healthcare Network / Metairie Multi-Specialty Clinic
        • Contato:
        • Investigador principal:
          • Tara Castellano
      • New Orleans, Louisiana, Estados Unidos, 70112
        • Recrutamento
        • University Medical Center New Orleans
        • Contato:
        • Investigador principal:
          • Tara Castellano
    • Massachusetts
      • Burlington, Massachusetts, Estados Unidos, 01805
      • Peabody, Massachusetts, Estados Unidos, 01960
        • Recrutamento
        • Lahey Clinic Peabody
        • Contato:
        • Investigador principal:
          • Andrew Piper-Vallillo
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Recrutamento
        • University of Michigan Rogel Cancer Center
        • Investigador principal:
          • Vaibhav Sahai
        • Contato:
      • Ann Arbor, Michigan, Estados Unidos, 48106
        • Recrutamento
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Battle Creek, Michigan, Estados Unidos, 49017
        • Recrutamento
        • Bronson Battle Creek
        • Contato:
        • Investigador principal:
          • Kathleen Y. Butler
      • Brighton, Michigan, Estados Unidos, 48114
        • Recrutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Brighton, Michigan, Estados Unidos, 48114
        • Recrutamento
        • Trinity Health Medical Center - Brighton
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Brownstown, Michigan, Estados Unidos, 48183
        • Recrutamento
        • Henry Ford Cancer Institute-Downriver
        • Contato:
        • Investigador principal:
          • Haythem Y. Ali
      • Canton, Michigan, Estados Unidos, 48188
        • Recrutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Canton, Michigan, Estados Unidos, 48188
        • Recrutamento
        • Trinity Health Medical Center - Canton
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Chelsea, Michigan, Estados Unidos, 48118
        • Recrutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Chelsea, Michigan, Estados Unidos, 48118
      • Clinton Township, Michigan, Estados Unidos, 48038
        • Recrutamento
        • Henry Ford Macomb Hospital-Clinton Township
        • Contato:
        • Investigador principal:
          • Haythem Y. Ali
      • Dearborn, Michigan, Estados Unidos, 48126
        • Recrutamento
        • Henry Ford Medical Center-Fairlane
        • Contato:
        • Investigador principal:
          • Haythem Y. Ali
      • Dearborn, Michigan, Estados Unidos, 48124
        • Recrutamento
        • Corewell Health Dearborn Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 248-551-7695
        • Investigador principal:
          • Andrew A. Muskovitz
      • Detroit, Michigan, Estados Unidos, 48202
        • Recrutamento
        • Henry Ford Hospital
        • Contato:
        • Investigador principal:
          • Haythem Y. Ali
      • Detroit, Michigan, Estados Unidos, 48201
        • Ativo, não recrutando
        • Wayne State University/Karmanos Cancer Institute
      • Detroit, Michigan, Estados Unidos, 48236
        • Recrutamento
        • Henry Ford Health Saint John Hospital
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • East China Township, Michigan, Estados Unidos, 48054
        • Recrutamento
        • Henry Ford River District Hospital
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • Farmington Hills, Michigan, Estados Unidos, 48334
        • Ativo, não recrutando
        • Weisberg Cancer Treatment Center
      • Farmington Hills, Michigan, Estados Unidos, 48336
        • Recrutamento
        • Corewell Health Farmington Hills Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 248-551-7695
        • Investigador principal:
          • Andrew A. Muskovitz
      • Flint, Michigan, Estados Unidos, 48503
        • Recrutamento
        • Genesys Hurley Cancer Institute
        • Contato:
          • Site Public Contact
          • Número de telefone: 810-762-8038
          • E-mail: wstrong@ghci.org
        • Investigador principal:
          • Tareq Al baghdadi
      • Flint, Michigan, Estados Unidos, 48503
        • Recrutamento
        • Hurley Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 810-762-8038
          • E-mail: wstrong@ghci.org
        • Investigador principal:
          • Tareq Al baghdadi
      • Flint, Michigan, Estados Unidos, 48503
        • Suspenso
        • Genesee Hematology Oncology PC
      • Flint, Michigan, Estados Unidos, 48503
        • Recrutamento
        • Cancer Hematology Centers - Flint
        • Contato:
          • Site Public Contact
          • Número de telefone: 810-762-8038
          • E-mail: wstrong@ghci.org
        • Investigador principal:
          • Tareq Al baghdadi
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Recrutamento
        • Trinity Health Grand Rapids Hospital
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Recrutamento
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
        • Contato:
        • Investigador principal:
          • Kathleen Y. Butler
      • Grosse Pointe Woods, Michigan, Estados Unidos, 48236
        • Recrutamento
        • Henry Ford Saint John Hospital - Breast
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Grosse Pointe Woods, Michigan, Estados Unidos, 48236
        • Recrutamento
        • Henry Ford Saint John Hospital - Academic
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • Grosse Pointe Woods, Michigan, Estados Unidos, 48236
        • Recrutamento
        • Henry Ford Saint John Hospital - Van Elslander
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • Jackson, Michigan, Estados Unidos, 49201
        • Recrutamento
        • Allegiance Health
        • Contato:
        • Investigador principal:
          • Haythem Y. Ali
      • Kalamazoo, Michigan, Estados Unidos, 49007
        • Recrutamento
        • Bronson Methodist Hospital
        • Contato:
        • Investigador principal:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Estados Unidos, 49007
        • Recrutamento
        • West Michigan Cancer Center
        • Contato:
        • Investigador principal:
          • Kathleen Y. Butler
      • Lansing, Michigan, Estados Unidos, 48910
        • Ativo, não recrutando
        • Karmanos Cancer Institute at McLaren Greater Lansing
      • Livonia, Michigan, Estados Unidos, 48154
        • Recrutamento
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Macomb, Michigan, Estados Unidos, 48044
        • Recrutamento
        • Henry Ford Warren Hospital - Breast Macomb
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • Macomb, Michigan, Estados Unidos, 48044
        • Recrutamento
        • Henry Ford Saint John Hospital - Macomb Medical
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • Muskegon, Michigan, Estados Unidos, 49444
        • Recrutamento
        • Trinity Health Muskegon Hospital
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Niles, Michigan, Estados Unidos, 49120
        • Recrutamento
        • Corewell Health Lakeland Hospitals - Niles Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 616-391-1230
        • Investigador principal:
          • Kathleen Y. Butler
      • Norton Shores, Michigan, Estados Unidos, 49444
        • Suspenso
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Novi, Michigan, Estados Unidos, 48377
        • Recrutamento
        • Henry Ford Medical Center-Columbus
        • Contato:
        • Investigador principal:
          • Haythem Y. Ali
      • Pontiac, Michigan, Estados Unidos, 48341
        • Recrutamento
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Reed City, Michigan, Estados Unidos, 49677
        • Recrutamento
        • Corewell Health Reed City Hospital
        • Contato:
        • Investigador principal:
          • Kathleen Y. Butler
      • Royal Oak, Michigan, Estados Unidos, 48073
        • Recrutamento
        • Corewell Health William Beaumont University Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 248-551-7695
        • Investigador principal:
          • Andrew A. Muskovitz
      • Saint Joseph, Michigan, Estados Unidos, 49085
        • Recrutamento
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
        • Contato:
        • Investigador principal:
          • Kathleen Y. Butler
      • Saint Joseph, Michigan, Estados Unidos, 49085
        • Recrutamento
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
        • Contato:
        • Investigador principal:
          • Kathleen Y. Butler
      • Traverse City, Michigan, Estados Unidos, 49684
        • Recrutamento
        • Munson Medical Center
        • Contato:
        • Investigador principal:
          • Kathleen Y. Butler
      • Troy, Michigan, Estados Unidos, 48085
        • Recrutamento
        • Corewell Health Beaumont Troy Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 248-551-7695
        • Investigador principal:
          • Andrew A. Muskovitz
      • Warren, Michigan, Estados Unidos, 48093
        • Recrutamento
        • Henry Ford Madison Heights Hospital - Breast
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • Warren, Michigan, Estados Unidos, 48093
        • Recrutamento
        • Henry Ford Health Warren Hospital
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • Warren, Michigan, Estados Unidos, 48093
        • Recrutamento
        • Henry Ford Warren Hospital - GLCMS
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • West Bloomfield, Michigan, Estados Unidos, 48322
        • Recrutamento
        • Henry Ford West Bloomfield Hospital
        • Contato:
        • Investigador principal:
          • Haythem Y. Ali
      • Wyandotte, Michigan, Estados Unidos, 48192
        • Recrutamento
        • Henry Ford Wyandotte Hospital
        • Investigador principal:
          • Haythem Y. Ali
        • Contato:
      • Wyoming, Michigan, Estados Unidos, 49519
        • Recrutamento
        • University of Michigan Health - West
        • Contato:
        • Investigador principal:
          • Kathleen Y. Butler
      • Ypsilanti, Michigan, Estados Unidos, 48106
      • Ypsilanti, Michigan, Estados Unidos, 48197
        • Recrutamento
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
    • Minnesota
      • Burnsville, Minnesota, Estados Unidos, 55337
        • Recrutamento
        • Minnesota Oncology - Burnsville
        • Contato:
        • Investigador principal:
          • David M. King
      • Duluth, Minnesota, Estados Unidos, 55805
        • Ativo, não recrutando
        • Saint Luke's Hospital of Duluth
      • Edina, Minnesota, Estados Unidos, 55435
        • Recrutamento
        • Fairview Southdale Hospital
        • Contato:
        • Investigador principal:
          • David M. King
      • Edina, Minnesota, Estados Unidos, 55435
        • Recrutamento
        • Minnesota Oncology - Edina
        • Contato:
        • Investigador principal:
          • David M. King
      • Minneapolis, Minnesota, Estados Unidos, 55407
        • Recrutamento
        • Abbott-Northwestern Hospital
        • Contato:
        • Investigador principal:
          • David M. King
      • Minneapolis, Minnesota, Estados Unidos, 55415
        • Recrutamento
        • Hennepin County Medical Center
        • Contato:
        • Investigador principal:
          • David M. King
      • Rochester, Minnesota, Estados Unidos, 55905
        • Recrutamento
        • Mayo Clinic in Rochester
        • Investigador principal:
          • Jacob Orme
        • Contato:
          • Site Public Contact
          • Número de telefone: 855-776-0015
      • Saint Louis Park, Minnesota, Estados Unidos, 55416
        • Recrutamento
        • Park Nicollet Clinic - Saint Louis Park
        • Contato:
        • Investigador principal:
          • David M. King
      • Saint Paul, Minnesota, Estados Unidos, 55101
        • Recrutamento
        • Regions Hospital
        • Contato:
        • Investigador principal:
          • David M. King
      • Saint Paul, Minnesota, Estados Unidos, 55102
        • Recrutamento
        • United Hospital
        • Contato:
        • Investigador principal:
          • David M. King
      • Shakopee, Minnesota, Estados Unidos, 55379
        • Recrutamento
        • Saint Francis Regional Medical Center
        • Contato:
        • Investigador principal:
          • David M. King
    • Missouri
      • Cape Girardeau, Missouri, Estados Unidos, 63703
        • Recrutamento
        • Saint Francis Medical Center
        • Investigador principal:
          • Bryan A. Faller
        • Contato:
          • Site Public Contact
          • Número de telefone: 573-334-2230
          • E-mail: sfmc@sfmc.net
      • Joplin, Missouri, Estados Unidos, 64804
        • Recrutamento
        • Mercy Hospital Joplin
        • Investigador principal:
          • Jay W. Carlson
        • Contato:
      • Springfield, Missouri, Estados Unidos, 65804
        • Recrutamento
        • Mercy Hospital Springfield
        • Investigador principal:
          • Jay W. Carlson
        • Contato:
          • Site Public Contact
          • Número de telefone: 417-269-4520
      • Springfield, Missouri, Estados Unidos, 65807
        • Recrutamento
        • CoxHealth South Hospital
        • Investigador principal:
          • Jay W. Carlson
        • Contato:
          • Site Public Contact
          • Número de telefone: 417-269-4520
      • St Louis, Missouri, Estados Unidos, 63128
        • Recrutamento
        • Mercy Hospital South
        • Investigador principal:
          • Jay W. Carlson
        • Contato:
    • Montana
      • Anaconda, Montana, Estados Unidos, 59711
        • Recrutamento
        • Community Hospital of Anaconda
        • Investigador principal:
          • John M. Schallenkamp
        • Contato:
      • Billings, Montana, Estados Unidos, 59101
        • Recrutamento
        • Billings Clinic Cancer Center
        • Investigador principal:
          • John M. Schallenkamp
        • Contato:
      • Billings, Montana, Estados Unidos, 59102
        • Recrutamento
        • Saint Vincent Frontier Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-648-6274
        • Investigador principal:
          • Patrick W. Cobb
      • Great Falls, Montana, Estados Unidos, 59405
        • Recrutamento
        • Benefis Sletten Cancer Institute
        • Investigador principal:
          • John M. Schallenkamp
        • Contato:
      • Kalispell, Montana, Estados Unidos, 59901
        • Recrutamento
        • Logan Health Medical Center
        • Investigador principal:
          • John M. Schallenkamp
        • Contato:
      • Missoula, Montana, Estados Unidos, 59804
        • Recrutamento
        • Community Medical Center
        • Investigador principal:
          • John M. Schallenkamp
        • Contato:
    • New Hampshire
      • Lebanon, New Hampshire, Estados Unidos, 03756
        • Recrutamento
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • Contato:
        • Investigador principal:
          • Kathryn C. Hourdequin
    • New York
      • Buffalo, New York, Estados Unidos, 14263
        • Ativo, não recrutando
        • Roswell Park Cancer Institute
      • New York, New York, Estados Unidos, 10029
        • Ativo, não recrutando
        • Mount Sinai Hospital
      • Stony Brook, New York, Estados Unidos, 11794
        • Ativo, não recrutando
        • Stony Brook University Medical Center
    • North Carolina
      • Cary, North Carolina, Estados Unidos, 27518
        • Suspenso
        • Duke Cancer Center Cary
      • Charlotte, North Carolina, Estados Unidos, 28203
        • Recrutamento
        • Carolinas Medical Center/Levine Cancer Institute
        • Investigador principal:
          • Earle F. Burgess
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-804-9376
      • Charlotte, North Carolina, Estados Unidos, 28210
        • Recrutamento
        • Atrium Health Pineville/LCI-Pineville
        • Investigador principal:
          • Earle F. Burgess
        • Contato:
          • Site Public Contact
          • Número de telefone: 980-442-2000
      • Charlotte, North Carolina, Estados Unidos, 28211
        • Recrutamento
        • Levine Cancer Institute-SouthPark
        • Investigador principal:
          • Earle F. Burgess
        • Contato:
          • Site Public Contact
          • Número de telefone: 980-442-2000
      • Charlotte, North Carolina, Estados Unidos, 28262
        • Recrutamento
        • Atrium Health University City/LCI-University
        • Investigador principal:
          • Earle F. Burgess
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-804-9376
      • Charlotte, North Carolina, Estados Unidos, 28277
        • Recrutamento
        • Levine Cancer Institute-Ballantyne
        • Investigador principal:
          • Earle F. Burgess
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-804-9376
      • Clinton, North Carolina, Estados Unidos, 28328
        • Recrutamento
        • Southeastern Medical Oncology Center-Clinton
        • Contato:
        • Investigador principal:
          • Samer S. Kasbari
      • Concord, North Carolina, Estados Unidos, 28025
        • Recrutamento
        • Atrium Health Cabarrus/LCI-Concord
        • Investigador principal:
          • Earle F. Burgess
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-804-9376
      • Durham, North Carolina, Estados Unidos, 27710
        • Recrutamento
        • Duke University Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 888-275-3853
        • Investigador principal:
          • Tucker Coston
      • Gastonia, North Carolina, Estados Unidos, 28054
        • Recrutamento
        • Levine Cancer Institute-Gaston
        • Investigador principal:
          • Earle F. Burgess
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-804-9376
      • Goldsboro, North Carolina, Estados Unidos, 27534
        • Recrutamento
        • Southeastern Medical Oncology Center-Goldsboro
        • Contato:
        • Investigador principal:
          • Samer S. Kasbari
      • Jacksonville, North Carolina, Estados Unidos, 28546
        • Recrutamento
        • Southeastern Medical Oncology Center-Jacksonville
        • Investigador principal:
          • Samer S. Kasbari
        • Contato:
      • Pinehurst, North Carolina, Estados Unidos, 28374
        • Recrutamento
        • FirstHealth of the Carolinas-Moore Regional Hospital
        • Contato:
        • Investigador principal:
          • Charles S. Kuzma
      • Raleigh, North Carolina, Estados Unidos, 27609
        • Recrutamento
        • Duke Cancer Center Raleigh
        • Contato:
        • Investigador principal:
          • Tucker Coston
      • Shelby, North Carolina, Estados Unidos, 28150
        • Recrutamento
        • Atrium Health Cleveland/LCI-Cleveland
        • Investigador principal:
          • Earle F. Burgess
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-804-9376
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • Ohio State University Comprehensive Cancer Center
        • Contato:
        • Investigador principal:
          • Bhavana Konda
      • Toledo, Ohio, Estados Unidos, 43623
        • Suspenso
        • Toledo Clinic Cancer Centers-Toledo
    • Oklahoma
      • Lawton, Oklahoma, Estados Unidos, 73505
        • Recrutamento
        • Cancer Centers of Southwest Oklahoma Research
        • Contato:
          • Site Public Contact
          • Número de telefone: 877-231-4440
        • Investigador principal:
          • Sagila George
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • Recrutamento
        • University of Oklahoma Health Sciences Center
        • Contato:
        • Investigador principal:
          • Sagila George
      • Oklahoma City, Oklahoma, Estados Unidos, 73120
        • Recrutamento
        • Mercy Hospital Oklahoma City
        • Investigador principal:
          • Jay W. Carlson
        • Contato:
          • Site Public Contact
          • Número de telefone: 405-752-3402
    • Oregon
      • Bend, Oregon, Estados Unidos, 97701
        • Recrutamento
        • Saint Charles Health System
        • Contato:
        • Investigador principal:
          • Charles W. Drescher
      • Clackamas, Oregon, Estados Unidos, 97015
        • Suspenso
        • Providence Cancer Institute Clackamas Clinic
      • Newberg, Oregon, Estados Unidos, 97132
        • Recrutamento
        • Providence Newberg Medical Center
        • Contato:
        • Investigador principal:
          • Charles W. Drescher
      • Oregon City, Oregon, Estados Unidos, 97045
        • Recrutamento
        • Providence Willamette Falls Medical Center
        • Contato:
        • Investigador principal:
          • Charles W. Drescher
      • Portland, Oregon, Estados Unidos, 97213
        • Recrutamento
        • Providence Portland Medical Center
        • Contato:
        • Investigador principal:
          • Charles W. Drescher
      • Portland, Oregon, Estados Unidos, 97225
        • Recrutamento
        • Providence Saint Vincent Medical Center
        • Contato:
        • Investigador principal:
          • Charles W. Drescher
    • Pennsylvania
      • Chambersburg, Pennsylvania, Estados Unidos, 17201
        • Recrutamento
        • WellSpan Medical Oncology and Hematology
        • Contato:
          • Site Public Contact
          • Número de telefone: 717-217-6020
        • Investigador principal:
          • Marianne Spengler
      • Ephrata, Pennsylvania, Estados Unidos, 17522
        • Recrutamento
        • Ephrata Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 717-721-4840
        • Investigador principal:
          • Marianne Spengler
      • Gettysburg, Pennsylvania, Estados Unidos, 17325
        • Recrutamento
        • Adams Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 877-441-7957
        • Investigador principal:
          • Marianne Spengler
      • Hanover, Pennsylvania, Estados Unidos, 17331
        • Recrutamento
        • WellSpan Medical Oncology and Hematology
        • Contato:
          • Site Public Contact
          • Número de telefone: 717-632-1559
        • Investigador principal:
          • Marianne Spengler
      • Lebanon, Pennsylvania, Estados Unidos, 17042
        • Recrutamento
        • Sechler Family Cancer Center
        • Contato:
        • Investigador principal:
          • Marianne Spengler
      • York, Pennsylvania, Estados Unidos, 17403
        • Recrutamento
        • WellSpan Health-York Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 877-441-7957
        • Investigador principal:
          • Marianne Spengler
      • York, Pennsylvania, Estados Unidos, 17403
        • Suspenso
        • Cancer Care Associates of York
    • Rhode Island
      • Westerly, Rhode Island, Estados Unidos, 02891
        • Recrutamento
        • Smilow Cancer Hospital Care Center - Westerly
        • Contato:
        • Investigador principal:
          • Matthew Austin
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Suspenso
        • Medical University of South Carolina
      • Rock Hill, South Carolina, Estados Unidos, 29732
        • Recrutamento
        • Levine Cancer Institute-Rock Hill
        • Investigador principal:
          • Earle F. Burgess
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-804-9376
    • South Dakota
      • Rapid City, South Dakota, Estados Unidos, 57701
        • Recrutamento
        • Rapid City Regional Hospital
        • Investigador principal:
          • Abdel-Ghani Azzouqa
        • Contato:
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Recrutamento
        • Vanderbilt University/Ingram Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-811-8480
        • Investigador principal:
          • Robert A. Ramirez
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • Recrutamento
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Contato:
        • Investigador principal:
          • Namrata I. Peswani
      • Dallas, Texas, Estados Unidos, 75235
        • Recrutamento
        • Parkland Memorial Hospital
        • Contato:
        • Investigador principal:
          • Namrata I. Peswani
      • Dallas, Texas, Estados Unidos, 75237
        • Recrutamento
        • UT Southwestern Simmons Cancer Center - RedBird
        • Investigador principal:
          • Namrata I. Peswani
        • Contato:
      • Fort Worth, Texas, Estados Unidos, 76104
        • Recrutamento
        • UT Southwestern/Simmons Cancer Center-Fort Worth
        • Contato:
        • Investigador principal:
          • Namrata I. Peswani
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • Investigador principal:
          • Tannaz Armaghany
        • Contato:
          • Site Public Contact
          • Número de telefone: 713-798-1354
          • E-mail: burton@bcm.edu
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Ben Taub General Hospital
        • Investigador principal:
          • Tannaz Armaghany
        • Contato:
          • Site Public Contact
          • Número de telefone: 713-873-2000
      • Richardson, Texas, Estados Unidos, 75080
        • Recrutamento
        • UT Southwestern Clinical Center at Richardson/Plano
        • Contato:
        • Investigador principal:
          • Namrata I. Peswani
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Recrutamento
        • Huntsman Cancer Institute/University of Utah
        • Contato:
        • Investigador principal:
          • Heloisa P. Soares
    • Vermont
      • Saint Johnsbury, Vermont, Estados Unidos, 05819
        • Recrutamento
        • Dartmouth Cancer Center - North
        • Contato:
        • Investigador principal:
          • Kathryn C. Hourdequin
    • Washington
      • Seattle, Washington, Estados Unidos, 98195
        • Recrutamento
        • University of Washington Medical Center - Montlake
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-804-8824
        • Investigador principal:
          • David B. Zhen
      • Seattle, Washington, Estados Unidos, 98109
        • Recrutamento
        • Fred Hutchinson Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-804-8824
        • Investigador principal:
          • David B. Zhen
    • West Virginia
      • Bridgeport, West Virginia, Estados Unidos, 26330
        • Recrutamento
        • United Hospital Center
        • Contato:
        • Investigador principal:
          • Nour Daboul
      • Morgantown, West Virginia, Estados Unidos, 26506
        • Recrutamento
        • West Virginia University Healthcare
        • Contato:
        • Investigador principal:
          • Nour Daboul
    • Wisconsin
      • Eau Claire, Wisconsin, Estados Unidos, 54701
      • La Crosse, Wisconsin, Estados Unidos, 54601
        • Recrutamento
        • Gundersen Lutheran Medical Center
        • Contato:
        • Investigador principal:
          • David E. Marinier
      • Marshfield, Wisconsin, Estados Unidos, 54449
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Recrutamento
        • Medical College of Wisconsin
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-805-3666
        • Investigador principal:
          • Alexandria T. Phan
      • Minocqua, Wisconsin, Estados Unidos, 54548
      • Rice Lake, Wisconsin, Estados Unidos, 54868
      • Stevens Point, Wisconsin, Estados Unidos, 54482
      • Weston, Wisconsin, Estados Unidos, 54476

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Participants must have histologically-confirmed (local site pathological confirmation sufficient) extrapulmonary poorly differentiated, neuroendocrine carcinoma (NEC)

  • Participants must have disease that is unresectable or metastatic and not eligible for definitive therapy as deemed per the treating investigator

  • Participants must have radiologically evaluable disease, measurable or non-measurable, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. All measurable and nonmeasurable lesions must be assessed by CT scan with IV contrast of the chest/abdomen/and pelvis (or CT chest without contrast and MRI abdomen/pelvis with gadolinium contrast, if contraindication to CT iodinated contrast) within 28 days prior to registration. While may be used for routine clinical evaluation, PET scans and bone scans alone are not acceptable for disease assessment while participating in this study. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form

  • Participants must have brain MRI (or CT head with contrast if there is contraindication to MRI brain) if clinically indicated within 28 days prior to registration. Note: Brain imaging is not required in participants without known and/or clinical concern for brain metastases. Participants with asymptomatic central nervous system (CNS) metastases are eligible if one or more of the following apply:

    • Participants who have received treatment for brain metastases must have:

      • No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
      • Discontinued all corticosteroids at least 14 days prior to registration
    • Participants with treatment-naive brain lesions must have:

      • No lesion measuring > 2.0 cm in size in any axis
      • MRI brain or CT head with contrast (if there is contraindication to MRI brain) demonstrating no evidence for mass effect, edema, or other impending neurological compromise within 28 days prior to registration
      • No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
      • No need for > 2 mg of dexamethasone (or equivalent of > 10 mg prednisone) per day at time of registration
  • Participants must not have symptomatic central nervous system (CNS) metastases

  • Participants must not have known or suspected leptomeningeal disease

  • Participants with prior history of non-metastatic (localized/locally advanced disease) extrapulmonary poorly differentiated NEC may have had prior platinum-based therapy +/- radiation +/- surgery provided that all therapy was completed >= 6 months prior to registration

  • Participants must discontinue denosumab prior to study registration and plan to replace with a bisphosphonate while on the study

  • Participants must not have had prior treatment for advanced or metastatic NEC EXCEPT one cycle of platinum (carboplatin/cisplatin) + etoposide is allowed prior to registration. Other chemotherapy regimens are not allowed. For participants with prostate or urothelial NEC, prior chemotherapy for the non-NEC component (e.g. adenocarcinoma or urothelial) is allowed as long as such therapy was completed >= 24 weeks prior to registration and participants have recovered from all prior toxicities to =< grade 1.

  • Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, antiPD-L2, CD137 agonists, anti-CTLA-4 agent, or any other immune checkpoint inhibitors for any neuroendocrine neoplasm. Immune checkpoint inhibitors given for other cancer indications are allowed provided last therapy was given at least 12 months prior to study registration

  • Participants must not have received treatment with systemic immunostimulatory agents including, but not limited to, interferon and interleukin2 [IL-2] within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to registration

  • Participants must not have had history of known severe allergy, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies, including to Chinese hamster ovary cell products or to any component of the atezolizumab formulation, cisplatin, carboplatin, or etoposide

  • Participants must not be on active systemic therapy for another cancer with the exception of hormonal therapy including androgen deprivation therapy (e.g., gonadotropin-releasing hormone [GnRH] agonists or antagonists), which can be continued while participants are receiving protocol therapy. Use of enzalutamide or apalutamide is permitted after completion of chemotherapy and must be held during chemotherapy for participants receiving prior to enrollment. Use of darolutamide is permitted during chemotherapy. Glucocorticoid-containing regimens, including abiraterone, are not permitted.

  • Participants must be >= 18 years of age

  • Participants must have a Zubrod performance status of =< 2 within 28 days prior to registration

  • Participants must have a complete medical history and physical exam within 28 days prior to registration

  • Absolute neutrophil count (ANC) >= 1.5 x 10^9 /L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Hemoglobin >= 9.0 g/dl (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Platelet count >= 100 x 10^9/L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (ULN) (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Serum total bilirubin =< 1.5 x ULN (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Adequate renal function as defined by any 1 of the following: 1) Measured creatinine clearance (CL) > 50 mL/min OR 2) Calculated creatinine CL > 50 mL/min by the Cockcroft-Gault formula OR by 24-hour urine collection for determination of creatinine clearance (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Participants must not have uncontrolled or symptomatic hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN) within 14 days prior to registration. Participants who have asymptomatic hypercalcemia are eligible provided that medical therapy to treat the hypercalcemia is planned

  • Participants must not have a diagnosis of immunodeficiency nor be receiving systemic steroid therapy (equivalent of > 20 mg of hydrocortisone per day) or any other form of immunosuppressive therapy within 14 days prior to registration

  • Participants must not have active or history of autoimmune disease or immune deficiency, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis with the following exceptions:

    • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study

    • Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study

    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

      • Rash must cover < 10% of body surface area
      • Disease is well controlled at baseline and requires only low-potency topical corticosteroids
      • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
  • Participants must not have history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. NOTE: History of radiation pneumonitis in the radiation field (fibrosis) is permitted

  • Participants must not have significant cardiovascular disease, such as New York Heart Association class II or greater cardiac disease, myocardial infarction within 3 months prior to registration, unstable arrythmias, or unstable angina

  • Participants must not have had a major surgical procedure other than for diagnosis within 28 days prior to registration. Participant must not plan to receive a major surgical procedure during the course of protocol treatment. NOTE: Patient port placement is not considered a major surgery

  • Participants must not have severe infections (i.e., Common Terminology Criteria for Adverse Events [CTCAE] grade >= 2) at time of registration, including but not limited to hospitalization for complications for infection, bacteremia, or severe pneumonia

  • Participants must not have known active tuberculosis

  • Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load, with testing performed as clinically indicated

  • Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV viral load, with testing performed as clinically indicated

  • Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load within 6 months of registration

  • Participants must not have prior allogeneic bone marrow transplantation or solid organ transplant

  • Participants must not have received administration of a live, attenuated vaccine (e.g., FluMist [registered trademark]) within 28 days prior to initiation of study treatment, during treatment with atezolizumab, and not plan to receive for 5 months after the last dose of atezolizumab

  • Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method (with details provided as a part of the consent process) during the treatment period and for 5 months after the final dose of atezolizumab. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

  • Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System

  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm I (atezolizumab, platinum drug, etoposide)

During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.

Given IV

Outros nomes:
  • Blastocarbe
  • Carboplat
  • Carboplatina Hexal
  • Carboplatina
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatina
  • Paraplatina AQ
  • Platinwas
  • Ribocarbo
  • JM8

Given IV

Outros nomes:
  • CDDP
  • Cis-diaminodicloridoplatina
  • Cismaplat
  • Cisplatina
  • Neoplatina
  • Platinol
  • Abiplatina
  • Blastolem
  • Briplatina
  • Cis-diamina-dicloroplatina
  • Cis-diaminodicloro Platina (II)
  • Cis-diaminodicloroplatina
  • Cis-dicloroamina Platina (II)
  • Dicloreto de diamina cisplatina
  • Cisplatina II
  • Dicloreto de diamina cisplatina II
  • Citoplatino
  • Citosina
  • Cysplatina
  • DDP
  • Lederplatina
  • Metaplatina
  • Cloreto de Peyrone
  • Sal de Peyrone
  • Placis
  • Plastistil
  • Platina
  • Platiblastina
  • Platiblastina-S
  • Platinex
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Diaminodicloreto de platina
  • Platiran
  • Platistina
  • Platosina

Undergo blood sample collection

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância Magnética (MRI)
  • ressonância magnética
  • Ressonância magnética (procedimento)
  • Ressonâncias magnéticas
  • RM estrutural

Given IV

Outros nomes:
  • Demetil epipodofilotoxina Etilidina glicosídeo
  • EPEG
  • Último
  • Toposar
  • Vepesid
  • PV 16
  • PV 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Undergo CT scan

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)
  • Diagnóstico Cat Scan
  • Tipo de serviço de varredura de gato diagnóstico

Given IV

Outros nomes:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA
  • RG-7446
  • RO-5541267
Experimental: Arm II (atezolizumab, platinum drug, etoposide, observation)

During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study. (CLOSED TO ACCRUAL 7/9/26)

Given IV

Outros nomes:
  • Blastocarbe
  • Carboplat
  • Carboplatina Hexal
  • Carboplatina
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatina
  • Paraplatina AQ
  • Platinwas
  • Ribocarbo
  • JM8

Given IV

Outros nomes:
  • CDDP
  • Cis-diaminodicloridoplatina
  • Cismaplat
  • Cisplatina
  • Neoplatina
  • Platinol
  • Abiplatina
  • Blastolem
  • Briplatina
  • Cis-diamina-dicloroplatina
  • Cis-diaminodicloro Platina (II)
  • Cis-diaminodicloroplatina
  • Cis-dicloroamina Platina (II)
  • Dicloreto de diamina cisplatina
  • Cisplatina II
  • Dicloreto de diamina cisplatina II
  • Citoplatino
  • Citosina
  • Cysplatina
  • DDP
  • Lederplatina
  • Metaplatina
  • Cloreto de Peyrone
  • Sal de Peyrone
  • Placis
  • Plastistil
  • Platina
  • Platiblastina
  • Platiblastina-S
  • Platinex
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Diaminodicloreto de platina
  • Platiran
  • Platistina
  • Platosina

Undergo blood sample collection

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância Magnética (MRI)
  • ressonância magnética
  • Ressonância magnética (procedimento)
  • Ressonâncias magnéticas
  • RM estrutural

Given IV

Outros nomes:
  • Demetil epipodofilotoxina Etilidina glicosídeo
  • EPEG
  • Último
  • Toposar
  • Vepesid
  • PV 16
  • PV 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Undergo CT scan

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)
  • Diagnóstico Cat Scan
  • Tipo de serviço de varredura de gato diagnóstico

Undergo observation

Outros nomes:
  • Observação
  • Vigilância Ativa
  • terapia adiada
  • gestão expectante
  • Espera vigilante

Given IV

Outros nomes:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA
  • RG-7446
  • RO-5541267
Comparador Ativo: Arm III (platinum drug, etoposide, observation)

During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.

Given IV

Outros nomes:
  • Blastocarbe
  • Carboplat
  • Carboplatina Hexal
  • Carboplatina
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatina
  • Paraplatina AQ
  • Platinwas
  • Ribocarbo
  • JM8

Given IV

Outros nomes:
  • CDDP
  • Cis-diaminodicloridoplatina
  • Cismaplat
  • Cisplatina
  • Neoplatina
  • Platinol
  • Abiplatina
  • Blastolem
  • Briplatina
  • Cis-diamina-dicloroplatina
  • Cis-diaminodicloro Platina (II)
  • Cis-diaminodicloroplatina
  • Cis-dicloroamina Platina (II)
  • Dicloreto de diamina cisplatina
  • Cisplatina II
  • Dicloreto de diamina cisplatina II
  • Citoplatino
  • Citosina
  • Cysplatina
  • DDP
  • Lederplatina
  • Metaplatina
  • Cloreto de Peyrone
  • Sal de Peyrone
  • Placis
  • Plastistil
  • Platina
  • Platiblastina
  • Platiblastina-S
  • Platinex
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Diaminodicloreto de platina
  • Platiran
  • Platistina
  • Platosina

Undergo blood sample collection

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância Magnética (MRI)
  • ressonância magnética
  • Ressonância magnética (procedimento)
  • Ressonâncias magnéticas
  • RM estrutural

Given IV

Outros nomes:
  • Demetil epipodofilotoxina Etilidina glicosídeo
  • EPEG
  • Último
  • Toposar
  • Vepesid
  • PV 16
  • PV 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Undergo CT scan

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)
  • Diagnóstico Cat Scan
  • Tipo de serviço de varredura de gato diagnóstico

Undergo observation

Outros nomes:
  • Observação
  • Vigilância Ativa
  • terapia adiada
  • gestão expectante
  • Espera vigilante

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Overall survival
Prazo: From date of registration or from date of start of observation/maintenance therapy to date of death due to any cause, assessed up to 5 years

Log-rank tests stratified by the randomization stratification factors will be used for null hypothesis (efficacy) tests. Cox regression models stratified by the randomization stratification factors will be used for alternative hypothesis (futility) tests.

From date of registration or from date of start of observation/maintenance therapy to date of death due to any cause, assessed up to 5 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Progression-free survival
Prazo: From date of registration or start of observation/maintenance therapy to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years

Will be estimated using the Kaplan-Meier method and compared using log-rank tests.

From date of registration or start of observation/maintenance therapy to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years
Duration of response
Prazo: Time from date of initial response to date of progression or death, assessed up to 5 years

Will be estimated non-parametrically using cumulative incidence curves.

Time from date of initial response to date of progression or death, assessed up to 5 years
Objective response rate (confirmed complete response [CR] or partial response [PR])
Prazo: Up to 5 years from study enrollment

Will be tabulated and compared between arms using Fisher's exact test.

Up to 5 years from study enrollment
Clinical benefit rate (confirmed CR or PR of any amount of time or stable disease for 6 months or longer)
Prazo: Up to 5 years from study enrollment

Will be tabulated and compared between arms using Fisher's exact test.

Up to 5 years from study enrollment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: David B Zhen, SWOG Cancer Research Network

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

28 de junho de 2022

Conclusão Primária (Estimado)

1 de outubro de 2028

Conclusão do estudo (Estimado)

1 de outubro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

25 de setembro de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

25 de setembro de 2021

Primeira postagem (Real)

28 de setembro de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever